Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | TACR1 | P25103 | 12/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26399598 | 1.00 | SIGMAR1 (0.48) | SIGMAR1TACR1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL5223921 | 0.89 | JAK2 (0.45) | SIGMAR1TACR1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL5223912 | 0.89 | JAK2 (0.45) | SIGMAR1TACR1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL5223918 | 0.89 | JAK2 (0.45) | SIGMAR1TACR1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL22721969 | 0.87 | SIGMAR1 (0.43) | SIGMAR1TACR1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL12435287 | 0.82 | OPRL1 (0.43) | TACR1CYP3A4CYP2D6CYP2C9OPRL1 | |
| SCHEMBL26399605 | 0.82 | OPRL1 (0.43) | TACR1CYP3A4CYP2D6CYP2C9OPRL1 | |
| SCHEMBL5259400 | 0.77 | SMN1; SMN2 (0.50) | TACR1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4405607 | 0.77 | SMN1; SMN2 (0.50) | TACR1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL5444025 | 0.74 | SIGMAR1 (0.43) | SIGMAR1TACR1CHRM2CHRM5CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178060-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178060-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME | NTSR2, BDKRB1, AVPR1B | SIGMAR1 344/4885TACR1 13/4885CYP3A4 3423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.